- Cash from operations increased 67.1% year-over-year to $858 million year-to-date, driven by higher operating income, a CARES Act tax credit, and timing of receipts and disbursements.
- Cash from operations increased 67.1% year-to-date to $858 million, driven by higher operating income and timing factors.
- Diagnostic information services revenues increased 15.7%, driven by acquisitions and organic growth in physician and hospital channels.
- Quest Diagnostics reported consolidated revenues of $2.76 billion in Q2 2025, up 15.2% year-over-year, with organic revenue growth of 5.2%.
- Reported EPS was $2.47, adjusted EPS was $2.62, both up significantly from prior year.
- Reported EPS was $2.47 versus $2.03 last year; adjusted EPS was $2.62 versus $2.35.
- Reported operating income was $438 million (15.9% margin), adjusted operating income was $466 million (16.9% margin).
- Reported operating income was $438 million (15.9% of revenues), up from $355 million (14.8%) last year; adjusted operating income was $466 million (16.9%), up from $398 million (16.6%).
- Revenue per requisition declined 0.4% due to LifeLabs acquisition but was up 3.3% organically, driven by more tests per requisition and test mix.
- Revenue per requisition declined 0.4% overall due to LifeLabs acquisition but was up 3.3% organically.
- Total volume increased 16.3%, with organic volume up 2.1%.
Related items and other data are not available for this feed item.
Dafinchi